Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 30

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 30
---
4 2023 % Var Reported Biopharma Net Revenues 1,687,487 1,492,423 13.1% Variation due to Exchange Rate Effects 30,377 Reported Biopharma Net Revenues at Constant Currency 1,717,864 1,492,423 15.1% In thousands of euros Q4 2024 Q4 2023 % Var Reported Diagnostic Net Revenues 166,063 172,498 (3.7%) Variation due to Exchange Rate Effects 2,979 Reported Diagnostic Net Revenues at Constant Currency 169,042 172,498 (2.0%) In thousands of euros Q4 2024 Q4 2023 % Var Reported Bio Supplies Net Revenues 52,404 41,285 26.9% Variation due to Exchange Rate Effects 874 Reported Bio Supplies Net Revenues at Constant Currency 53,278 41,285 29.0% In thousands of euros Q4 2024 Q4 2023 % Var Reported Others & Intersegments Net Revenues 69,860 63,344 10.3% Variation due to Exchange Rate Effects 594 Reported Other & Intersegments Net Revenues at Constant Currency 70,454 63,344 11.2% In thousands of euros Q4 2024 Q4 2023 % Var Reported U.S. + Canada Net Revenues 1,079,798 1,005,889 7.3% Variation due to Exchange Rate Effects 23,632 Reported U.S. + Canada Net Revenues at Constant Currency 1,103,430 1,005,889 9.7% In thousands of euros Q4 2024 Q4 2023 % Var Reported EU Net Revenues 431,668 338,972 27.3% Variation due to Exchange Rate Effects 289 Reported EU Net Revenues at Constant Currency 431,957 338,972 27.4% In thousands of euros Q4 2024 Q4 2023 % Var Reported ROW Net Revenues 464,348 424,689 9.3% Variation due to Exchange Rate Effects 10,902 Reported ROW Net Revenues at Constant Currency 475,250 424,689 11.9% Introductory Remarks Business Performance Financials Final remarks Annex

- 41 - Q4 2024 Results Net Revenue Reconciliation at cc | 2024 In thousands of euros 202